Immune Phenotypes and Target Antigens of Clonally Expanded Bone Marrow T Cells in Treatment-Naïve Multiple Myeloma.

Autor: Welters C; Department of Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Lammoglia Cobo MF; Department of Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Stein CA; Department of Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Hsu MT; Molecular Immunology and Gene Therapy, Max-Delbrück-Center for Molecular Medicine (MDC) Berlin, Germany., Ben Hamza A; Department of Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Penter L; Department of Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Dana-Farber Cancer Institute, Boston, Massachusetts., Chen X; Molecular Immunology and Gene Therapy, Max-Delbrück-Center for Molecular Medicine (MDC) Berlin, Germany., Buccitelli C; Proteomics Platform, Max-Delbrück-Center for Molecular Medicine and Berlin Institute of Health, Berlin, Germany., Popp O; Proteomics Platform, Max-Delbrück-Center for Molecular Medicine and Berlin Institute of Health, Berlin, Germany., Mertins P; Proteomics Platform, Max-Delbrück-Center for Molecular Medicine and Berlin Institute of Health, Berlin, Germany., Dietze K; Department of Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Bullinger L; Department of Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany., Moosmann A; Department of Medicine III, Klinikum der Universität München, Munich, Germany.; German Center for Infection Research (DZIF), Munich, Germany., Blanc E; Core Unit Bioinformatics, Berlin Institute of Health, Berlin, Germany., Beule D; Core Unit Bioinformatics, Berlin Institute of Health, Berlin, Germany., Gerbitz A; Hans Messner Allogeneic Stem Cell Transplant Program, Princess Margaret Cancer Centre, Toronto, Canada., Strobel J; Department of Transfusion Medicine and Hemostaseology, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany., Hackstein H; Department of Transfusion Medicine and Hemostaseology, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany., Rahn HP; Preparative Flow Cytometry, Max-Delbrück-Centrum für Molekulare Medizin, Berlin, Germany., Dornmair K; Institute of Clinical Neuroimmunology, University Hospital and Biomedical Center, LMU Munich, Germany., Blankenstein T; Molecular Immunology and Gene Therapy, Max-Delbrück-Center for Molecular Medicine (MDC) Berlin, Germany., Hansmann L; Department of Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.

Publikováno v: Cancer immunology research [Cancer Immunol Res] 2022 Nov 02; Vol. 10 (11), pp. 1407-1419.

Reconstitution of EBV-directed T cell immunity by adoptive transfer of peptide-stimulated T cells in a patient after allogeneic stem cell transplantation for AITL.

Autor: Lammoglia Cobo MF; Department of Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Ritter J; Institute of Pathology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Gary R; Department of Internal Medicine 5 -Hematology/Oncology, University Hospital Erlangen, Erlangen, Germany., Seitz V; Institute of Pathology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; HS Diagnomics GmbH, Berlin, Germany., Mautner J; Department of Medicine III, LMU-Klinikum, Munich, Germany.; German Centre for Infection Research, Munich, Germany., Aigner M; Department of Internal Medicine 5 -Hematology/Oncology, University Hospital Erlangen, Erlangen, Germany., Völkl S; Department of Internal Medicine 5 -Hematology/Oncology, University Hospital Erlangen, Erlangen, Germany., Schaffer S; Department of Internal Medicine 5 -Hematology/Oncology, University Hospital Erlangen, Erlangen, Germany., Moi S; Department of Internal Medicine 5 -Hematology/Oncology, University Hospital Erlangen, Erlangen, Germany., Seegebarth A; Institute of Pathology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Bruns H; Department of Internal Medicine 5 -Hematology/Oncology, University Hospital Erlangen, Erlangen, Germany., Rösler W; Department of Internal Medicine 5 -Hematology/Oncology, University Hospital Erlangen, Erlangen, Germany., Amann K; Department of Nephropathology, Institute of Pathology, University of Erlangen, Erlangen, Germany., Büttner-Herold M; Department of Nephropathology, Institute of Pathology, University of Erlangen, Erlangen, Germany., Hennig S; HS Diagnomics GmbH, Berlin, Germany., Mackensen A; Department of Internal Medicine 5 -Hematology/Oncology, University Hospital Erlangen, Erlangen, Germany., Hummel M; Institute of Pathology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Moosmann A; Department of Medicine III, LMU-Klinikum, Munich, Germany.; German Centre for Infection Research, Munich, Germany., Gerbitz A; Division of Medical Oncology and Hematology, Princess Margaret Cancer Center, Toronto, Ontario, Canada.

Publikováno v: PLoS pathogens [PLoS Pathog] 2022 Apr 22; Vol. 18 (4), pp. e1010206. Date of Electronic Publication: 2022 Apr 22 (Print Publication: 2022).

Cheminformatic Analysis of Antimalarial Chemical Space Illuminates Therapeutic Mechanisms and Offers Strategies for Therapy Development.

Autor: Varela JN; Department of Chemical & Biological Engineering, The University of British Columbia , Vancouver, BC, Canada , V6T 1Z3., Lammoglia Cobo MF; Department of Chemical & Biological Engineering, The University of British Columbia , Vancouver, BC, Canada , V6T 1Z3.; Life Sciences Department, Monterrey Institute of Technology and Higher Education , Mexico City Campus, Mexico City, Mexico , 14380., Pawar SV; Department of Chemical & Biological Engineering, The University of British Columbia , Vancouver, BC, Canada , V6T 1Z3., Yadav VG; Department of Chemical & Biological Engineering, The University of British Columbia , Vancouver, BC, Canada , V6T 1Z3.; Neglected Global Diseases Initiative, The University of British Columbia , Vancouver, BC, Canada , V6T 1Z3.

Publikováno v: Journal of chemical information and modeling [J Chem Inf Model] 2017 Sep 25; Vol. 57 (9), pp. 2119-2131. Date of Electronic Publication: 2017 Aug 29.